
Lenmeldy, GLP-1s and Oprah, autoimmune disease
Adam’s Biotech Scorecard is a new newsletter offering insights on the biotech industry by senior reporter Adam Feuerstein. In the latest issue, topics include FDA approval for Akebia Therapeutics’ Vafseo, Gilead Sciences licensing an experimental cancer drug, and the world’s costliest drug, Lenmeldy, priced at $4.25 million. The newsletter also discusses immune senescence and potential…